Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    0.00 (0.00%)
Bid:
26.10
Ask:
27.40
Spread: 1.30 (4.981%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Board Changes

27 Apr 2026 07:00

RNS Number : 9952B
EKF Diagnostics Holdings PLC
27 April 2026
 

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Board Changes

Appointment of Chief Financial Officer

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, announces the appointment of Helen Jones FCA as Chief Financial Officer ("CFO"). Helen will join the Board and assume the role of CFO with immediate effect.

 

Helen Jones is an experienced CFO with over 20 years' experience leading finance, operations, and strategic transactions in high-growth, technology-driven AIM listed businesses.

 

Helen joins EKF from Surgical Science, a leading provider of medical simulation solutions, where she has assumed a senior Group-level role following its acquisition of Intelligent Ultrasound Group plc in February 2025, with responsibility spanning post-acquisition integration and operational cost reduction, Group statutory reporting, and sustainability leadership. Prior to the acquisition, Helen spent five years as CFO of Intelligent Ultrasound Group plc, an AIM-listed company supplying simulation and AI-based ultrasound training solutions to the healthcare sector. During her tenure, Helen led two successful equity placings to fund growth and innovation, played a central role in both the £40.6 million divestment of its Clinical AI division to GE Healthcare and the subsequent sale of the Simulation business to Surgical Science.

 

Before joining Intelligent Ultrasound, Helen held a senior finance role within AIM-listed oil and exploration company Amerisur Resources plc and prior to that spent 11 years in various senior financial positions at Tata Steel Europe. Helen is a fellow of the Institute of Chartered Accountants in England and Wales having trained and qualified with PwC in 2004.

 

Helen succeeds Stephen Young, who is retiring from the Board. Steve will be available to support Helen to ensure a smooth handover but will step down from the Board with immediate effect. The Board would like to extend its sincere thanks to Steve for his financial stewardship since joining the Company in September 2023 and wishes him well in his retirement.

 

 

Commenting, Gavin Jones, Chief Executive Officer, said: "We are delighted to welcome Helen to the EKF team at a key time as we execute on our five-year development plan for accelerated growth. Helen's track record in listed healthcare technology businesses, her experience executing complex transactions, and her capital markets expertise make her an excellent fit for EKF as we accelerate our five-year plan. Her appointment reflects our commitment to building a leadership team capable of delivering our ambitious growth targets."

 

Additional Disclosures Required under the AIM Rules for Companies

The following additional information is provided with regards to the appointment of Helen Mary Kinsey Jones (aged 47) in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

 

Current Directorships/partnerships

Directorships/partnerships within the last five years:

None

IML Finance Limited

Intelligent Ultrasound Innovations Limited

Intelligent Ultrasound Limited

Intelligent Ultrasound North America Inc

Inventive Medical Limited

Medaphor International Limited

Surgical Science UK Limited

Surgical Science UK Holdings Limited

 

Helen does not hold any shares or options in the Company.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

The person responsible for arranging the release of this Announcementon behalf of the Company is Gavin Jones, Chief Executive Officer.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Gavin Jones, Chief Executive Officer

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Patrick Weaver

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

Point-of-Care analysers in the key areas of Hematology and Diabetes 

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAESMEMSEFL
Date   Source Headline
27th Apr 20207:00 amRNSUpdate on COVID-19 related manufacturing contract
7th Apr 20207:00 amRNSFinal Results
24th Mar 20207:00 amRNSDetailed trading review including COVID-19 update
20th Mar 20207:00 amRNSInvestor results briefing update
4th Mar 20207:00 amRNSNotice of Results
24th Feb 20201:56 pmRNSHolding(s) in Company
29th Jan 20207:00 amRNSTrading update
6th Nov 201912:14 pmRNSTrading update and performance bonuses
10th Sep 20197:00 amRNSHalf-year Report
10th Sep 20197:00 amRNSPreferred Partner Arrangement with Mount Sinai
21st Aug 20197:00 amRNSNotice of Results
8th Aug 20194:40 pmRNSSecond Price Monitoring Extn
8th Aug 20194:35 pmRNSPrice Monitoring Extension
15th Jul 20197:00 amRNSTrading update
11th Jun 20192:15 pmRNSCancellation of share options
7th Jun 20194:30 pmRNSHolding(s) in Company
28th May 20197:00 amRNSDirector/PDMR Shareholding
2nd May 201911:21 amRNSResult of AGM
26th Apr 20196:20 pmRNSAcquisition of further interest in Renalytix AI
25th Apr 20197:00 amRNSPosting of AR & Accounts and Notice of AGM
13th Mar 20197:00 amRNSFinal Results
8th Mar 20197:00 amRNSNotice of Results
20th Feb 20197:00 amRNSUS FDA approval for Quo-Test analyser
22nd Jan 20197:00 amRNSUpdate on McKesson US distribution agreement
21st Jan 20197:00 amRNSClarification re. lock-up restrictions
16th Jan 20197:00 amRNSTrading update
20th Dec 20187:00 amRNSUpdate regarding planned change of NOMAD
19th Dec 20184:56 pmRNSPDMR dealing
7th Dec 20183:15 pmRNSPurchase of own shares and PDMR Dealing
30th Nov 20182:35 pmRNSTotal Voting Rights
22nd Nov 20185:13 pmRNSPurchase of own shares and PDMR Dealing
21st Nov 20182:08 pmRNSPurchase of own shares and PDMR Dealing
20th Nov 20185:18 pmRNSPurchase of own shares and PDMR Dealing
14th Nov 20182:20 pmRNSShare Buy-Back
9th Nov 20181:48 pmRNSDirector/PDMR Shareholding
6th Nov 20187:00 amRNSRENX Admission to AIM and First Day of Dealings
2nd Nov 20188:00 amRNSSchedule 1 update - Renalytix AI plc
1st Nov 20185:30 pmRNSUpdate regarding AIM admission of RenalytixAI
31st Oct 20186:00 pmRNSResult of RO by RenalytixAI & Fundraising Update
23rd Oct 20182:00 pmRNSSchedule One Update - Renalytix AI plc
23rd Oct 201811:01 amRNSUpdate to distribution timetable
22nd Oct 20185:23 pmRNSApproval of distribution of shares in RenalytixAI
19th Oct 201812:10 pmRNSResult of General Meeting
19th Oct 201811:00 amRNSSchedule One - Renalytix AI plc
12th Oct 20187:00 amRNSInvestor presentation
11th Oct 20186:03 pmRNSLaunch of Restricted Offer by Renalytix AI plc
11th Oct 20185:21 pmRNSFundraising and AIM admission of Renalytix AI plc
11th Oct 20184:01 pmRNSFundraising and AIM admission of Renalytix AI plc
27th Sep 201810:15 amRNSNotice of GM
19th Sep 20187:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.